G
G. Michael Besser
Researcher at St Bartholomew's Hospital
Publications - 41
Citations - 4565
G. Michael Besser is an academic researcher from St Bartholomew's Hospital. The author has contributed to research in topics: Pituitary gland & Acromegaly. The author has an hindex of 30, co-authored 41 publications receiving 4321 citations. Previous affiliations of G. Michael Besser include Queen Mary University of London.
Papers
More filters
Journal ArticleDOI
The diagnosis and medical management of advanced neuroendocrine tumors.
TL;DR: Assessment of specific or general tumor markers offers high sensitivity in establishing the diagnosis and can also have prognostic significance, and therapy with radionuclides may be used for tumors exhibiting uptake to a diagnostic scan, either after surgery to eradicate microscopic residual disease or later if conventional treatment or biotherapy fails.
Journal ArticleDOI
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
Aart Jan van der Lely,R. Kent Hutson,Peter J Trainer,G. Michael Besser,Ariel L. Barkan,Laurence Katznelson,Anne Klibanski,Vivien Herman-Bonert,Shlomo Melmed,Mary Lee Vance,Pamela U. Freda,Paul M Stewart,Keith E Friend,David R. Clemmons,Gudmundur Johannsson,Stavros Stavrou,David M. Cook,Lawrence S. Phillips,Christian J. Strasburger,Suzanne Hacker,Kenneth A. Zib,Robert J. Davis,John A. Scarlett,Michael O. Thorner +23 more
TL;DR: Pegvisomant is an effective medical treatment for acromegaly and of the patients treated for 12 months or more, 87 of 90 (97%) achieved a normal serum IGF-1 concentration.
Journal ArticleDOI
The Ectopic Adrenocorticotropin Syndrome: Clinical Features, Diagnosis, Management, and Long-Term Follow-Up
Andrea M. Isidori,Gregory Kaltsas,Carlotta Pozza,Vanni Frajese,John Newell-Price,Rodney H. Reznek,Paul Jenkins,John P. Monson,Ashley B. Grossman,G. Michael Besser +9 more
TL;DR: A variety of tests and imaging studies are necessary for the correct diagnosis of the EAS, but up to 20% of cases present a covert or occult EAS syndrome, and these cases require a prolonged follow-up, review, and repetition of diagnostic tests and scans.
Journal ArticleDOI
Interleukins-1 and -6 stimulate the release of corticotropin-releasing hormone-41 from rat hypothalamus in vitro via the eicosanoid cyclooxygenase pathway.
Pierluigi Navarra,S. Tsagarakis,Manuel S. Faria,Lesley H. Rees,G. Michael Besser,Ashley B. Grossman +5 more
TL;DR: IL-6, like IL-1, can exert a potent enhancing effect on the HPA by acutely stimulating the secretion of CRH-41 from the hypothalamus at a site above the level of the median eminence, at concentrations known to occur in human plasma and cerebrospinal fluid.
Journal ArticleDOI
Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors.
Kulbir Lidhar,Márta Korbonits,Suzanne Jordan,Zamira Khalimova,Gregory Kaltsas,Xin Lu,Richard N. Clayton,Paul J. Jenkins,John P. Monson,G. Michael Besser,David G. Lowe,Ashley B. Grossman +11 more
TL;DR: It is concluded that pituitary adenomas show a lower level of p 27 protein expression than the normal cells from which they are derived, with malignant transformation leading to complete loss of p27 immunoreactivity.